Table 3.
Cox regression of progression-free survival after first-line gefitinib therapy
| N | Multivariate Step down procedure |
||
|---|---|---|---|
| HR | 95% CI | ||
| Sex | |||
| Male | 269 | Ref | – |
| Female | 654 | 0.812 | (0.697, 0.946) |
| Histology | |||
| Ad | 893 | Ref | – |
| Other | 30 | 1.858 | (1.266, 2.725) |
| Clinical stage | |||
| IIIB | 44 | Ref | – |
| IV | 595 | 1.747 | (1.227, 2.486) |
| Recurrent | 284 | 0.961 | (0.664, 1.391) |
| Performance status | |||
| 0 | 334 | Ref | – |
| 1 | 365 | 1.441 | (1.221, 1.701) |
| 2 | 85 | 2.125 | (1.640, 2.754) |
| 3 | 69 | 2.388 | (1.789, 3.187) |
| 4 | 11 | 1.769 | (0.898, 3.484) |
| Unknown | 59 | 0.928 | (0.680, 1.268) |
HR, hazard ratio; CI, confidential interval; Ad, adenocarcinoma.